Completed PHASE4 INTERVENTIONAL 2-arm NCT00126516

Angiotensin II Receptor Blockers (ARB) and ACE Inhibitors (ACEI) on Silent Brain Infarction and Cognitive Decline

Effects of Angiotensin II Receptor Blockers (ARB) and Angiotensin Converting Enzyme Inhibitors (ACEI) on Progression of Silent Brain Infarction and Cognitive Decline in Japanese Patients With Essential Hypertension in the Elderly

Sponsor: Nara Medical University

Conditions Brain Infarction Hypertension

Interventions Angiotensin II Receptor Antagonists Angiotensin-converting Enzyme Inhibitors

Updated 5 times since 2017 Last updated: Oct 28, 2013 Started: May 31, 2004 Primary completion: Jun 30, 2013 Completion: Jun 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Brain Infarction and Hypertension and is currently completed. Nara Medical University leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

May 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nara Medical University

Data source: Nara Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kashihara, Japan